Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OptumRx Inc.
Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.
Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER
There are as many rare disease patients as there are diabetics, Cigna’s Steve Miller notes, arguing that exorbitant prices for each treatment could drive counterproductive categorical exclusions by payers.